CapOpus is the name of a randomized controlled trial (RCT) running in Denmark at Psychiatric Center Bispebjerg (part of Region Hovedstadens Psykiatri) and physically located at Bispebjerg Hospital in Copenhagen. It is an intervention aimed at reducing cannabis consumption in young persons with comorbid severe mental illness such as schizophrenia or schizotypal personality disorder, and cannabis dependency. It is run by professor, psychiatrist Merete Nordentoft, MD, PhD.
The aim of the RCT is to compare an approach using motivational interviewing, cognitive behaviour therapy, and the stages of change model compared with standard treatment. Among the trial's funders are the Lundbeck foundation, the Municipality of Copenhagen, and Sygekassernes Helsefond.
The primary outcome of the trial is reduction in number of days using cannabis, as measured by the timeline followback instrument. As secondary outcomes, the trial measures level of psychopathology in terms of positive and negative symptoms with the PANSS instrument; cognitive function using a set of validated tests; and quality of life and related life-areas measured with the Manchester Short Assessment of Quality of Life instrument and the World Health Organisation's Disability Assessment Schedule.
The presence of mental illness and cannabis dependency, abuse, or harmful use is established using the SCAN interview's chapters 11 and 12.
- CapOpus - in both Danish and English
- Hjorthøj C; Fohlmann A, Larsen AM, Madsen MT, Vesterager L, Gluud C, Arendt MC, Nordentoft M (2008). "Design paper: The CapOpus trial: A randomized, parallel-group, observer-blinded clinical trial of specialized addiction treatment versus treatment as usual for young patients with cannabis abuse and psychosis". Trials 9: 42. doi:10.1186/1745-6215-9-42. PMC 2475529. PMID 18620563. http://www.trialsjournal.com/content/pdf/1745-6215-9-42.pdf. Retrieved 2008-08-06.
- Nordentoft M; Hjorthøj C (2007). "Cannabis use and risk of psychosis in later life". The Lancet 370 (9584): 293–4. doi:10.1016/S0140-6736(07)61135-0. PMID 17662860.